Megan Eb Clowse1, Amanda M Eudy1, Jessica Revels2, Gillian D Sanders3,4,5, Lisa Criscione-Schreiber1. 1. Division of Rheumatology & Immunology, Department of Medicine, Duke University Medical Center, Durham, USA. 2. Duke Office of Clinical Research, Duke University School of Medicine, Durham, USA. 3. Department of Population Health Sciences, Duke University, Durham, USA. 4. Duke Clinical Research Institute, Duke University, Durham, USA. 5. Duke-Margolis Center for Health Policy, Duke University, Durham, USA.
Abstract
INTRODUCTION: Rheumatologists are essential partners in planning and managing pregnancies in women with lupus. Whether they know the essentials of contraceptive and medical treatment in pregnancy, however, is unknown. METHOD: Anonymous in-lecture surveys were completed by 270 rheumatologists to assess knowledge of contraceptive effectiveness, emergency contraception, medication teratogenicity, and lupus pregnancy risk assessment. RESULTS: Rheumatologists knew the high effectiveness of the intrauterine device, but over-estimated the effectiveness of injectable medroxyprogesterone and condoms. Almost all identified methotrexate as a teratogen, but only 69% identified cyclophosphamide and 37% mycophenolate. Most rheumatologists knew that lupus activity in pregnancy is the main predictor of pregnancy outcomes, but underestimated the risks of hypertension and race. CONCLUSION: To improve lupus pregnancy planning and management, rheumatologists would benefit from improved knowledge about contraceptive effectiveness, teratogens, and the risks from non-lupus factors for pregnancy complications.
INTRODUCTION: Rheumatologists are essential partners in planning and managing pregnancies in women with lupus. Whether they know the essentials of contraceptive and medical treatment in pregnancy, however, is unknown. METHOD: Anonymous in-lecture surveys were completed by 270 rheumatologists to assess knowledge of contraceptive effectiveness, emergency contraception, medication teratogenicity, and lupus pregnancy risk assessment. RESULTS: Rheumatologists knew the high effectiveness of the intrauterine device, but over-estimated the effectiveness of injectable medroxyprogesterone and condoms. Almost all identified methotrexate as a teratogen, but only 69% identified cyclophosphamide and 37% mycophenolate. Most rheumatologists knew that lupus activity in pregnancy is the main predictor of pregnancy outcomes, but underestimated the risks of hypertension and race. CONCLUSION: To improve lupus pregnancy planning and management, rheumatologists would benefit from improved knowledge about contraceptive effectiveness, teratogens, and the risks from non-lupus factors for pregnancy complications.
Entities:
Keywords:
Rheumatology; contraception; high-risk pregnancy; medical education
Authors: Nicole M Sifontis; Lisa A Coscia; Serban Constantinescu; Antonella F Lavelanet; Michael J Moritz; Vincent T Armenti Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: Jill P Buyon; Mimi Y Kim; Marta M Guerra; Carl A Laskin; Michelle Petri; Michael D Lockshin; Lisa Sammaritano; D Ware Branch; T Flint Porter; Allen Sawitzke; Joan T Merrill; Mary D Stephenson; Elisabeth Cohn; Lamya Garabet; Jane E Salmon Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: Christina D Chambers; Diana L Johnson; Luther K Robinson; Stephen R Braddock; Ronghui Xu; Janina Lopez-Jimenez; Nicole Mirrasoul; Elizabeth Salas; Yunjun J Luo; Shelia Jin; Kenneth Lyons Jones Journal: Arthritis Rheum Date: 2010-05
Authors: Anna E DeNoble; Kelli S Hall; Xiao Xu; Melissa K Zochowski; Kenneth Piehl; Vanessa K Dalton Journal: Obstet Gynecol Date: 2014-06 Impact factor: 7.661
Authors: Kathryn M Curtis; Naomi K Tepper; Tara C Jatlaoui; Erin Berry-Bibee; Leah G Horton; Lauren B Zapata; Katharine B Simmons; H Pamela Pagano; Denise J Jamieson; Maura K Whiteman Journal: MMWR Recomm Rep Date: 2016-07-29
Authors: L Andreoli; G K Bertsias; N Agmon-Levin; S Brown; R Cervera; N Costedoat-Chalumeau; A Doria; R Fischer-Betz; F Forger; M F Moraes-Fontes; M Khamashta; J King; A Lojacono; F Marchiori; P L Meroni; M Mosca; M Motta; M Ostensen; C Pamfil; L Raio; M Schneider; E Svenungsson; M Tektonidou; S Yavuz; D Boumpas; A Tincani Journal: Ann Rheum Dis Date: 2016-07-25 Impact factor: 19.103
Authors: Mehret Birru Talabi; Megan E B Clowse; Susan J Blalock; Megan Hamm; Sonya Borrero Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Katherine P Pryor; Bill Albert; Sonali Desai; Susan Y Ritter; Laura Tarter; Jonathan Coblyn; Bonnie L Bermas; Leah M Santacroce; Caryn Dutton; Kari P Braaten; Lydia E Pace; Kathryn Rexrode; Elizabeth Janiak; Candace H Feldman Journal: ACR Open Rheumatol Date: 2022-05-31